| __timestamp | Genmab A/S | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 381287000 |
| Thursday, January 1, 2015 | 91224000 | 452612000 |
| Friday, January 1, 2016 | 102413000 | 316800000 |
| Sunday, January 1, 2017 | 146987000 | 330100000 |
| Monday, January 1, 2018 | 213695000 | 265800000 |
| Tuesday, January 1, 2019 | 342000000 | 336200000 |
| Wednesday, January 1, 2020 | 661000000 | 423900000 |
| Friday, January 1, 2021 | 1283000000 | 467000000 |
| Saturday, January 1, 2022 | 2676000000 | 487000000 |
| Sunday, January 1, 2023 | 3297000000 | 477100000 |
| Monday, January 1, 2024 | 3790000000 |
Data in motion
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, United Therapeutics Corporation and Genmab A/S have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Genmab's SG&A expenses skyrocketed by over 4,000%, peaking at approximately 3.3 billion in 2023. This surge reflects Genmab's aggressive expansion and investment in market penetration. In contrast, United Therapeutics maintained a more stable trajectory, with expenses increasing by a modest 25% over the same period, reaching around 477 million in 2023. This stability underscores United Therapeutics' focus on cost management and operational efficiency. The divergent paths of these two companies highlight the strategic choices in managing operational costs, offering valuable insights into their business models and market strategies.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated